Publication details

<< back
 

BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

Basic information
Original title:BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Authors:Pavel Šimara, Martina Peterková, Stanislav Stejskal, Michaela Potěšilová, Irena Krontorád Koutná, Zdeněk Ráčil, Filip Rázga, Tomáš Jurček, Dana Dvořáková, Jiří Mayer
Further information
Citation:ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ and Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma, England: Informa Healthcare, 2012, vol. 53, No 8, p. 1627-1629. ISSN 1042-8194. doi:10.3109/10428194.2012.656104.Export BibTeX
@article{979222,
author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří},
article_location = {England},
article_number = {8},
doi = {http://dx.doi.org/10.3109/10428194.2012.656104},
keywords = {p-CrkL; chronic myeloid leukemia; imatinib},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & lymphoma},
title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112},
volume = {53},
year = {2012}
}
Original language:English
Field:Oncology and hematology
WWW:link to a new windowhttp://www.ncbi.nlm.nih.gov/pubmed/22233112
Type:Article in Periodical
Keywords:p-CrkL; chronic myeloid leukemia; imatinib

In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.

Related projects:

 
 
top